The Direct Molecular Target for Imipridone ONC201 Is Finally Established.
In this issue of Cancer Cell, Ishizawa et al. describe the hyperactivation of ClpP as a strategy in cancer therapy. They discovered ONC201, a clinical-stage compound, as a potent activator of ClpP and established that ClpP activation is responsible for the antitumor activity of imipridone ONC201.